Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | YAP1 | P46937 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4874370 | 0.94 | JAK2 (0.46) | USP30BACE1BACE2GPR119PRMT5 | |
| SCHEMBL4862367 | 0.91 | YAP1 (0.42) | USP30BACE1BACE2GPR119PRMT5 | |
| SCHEMBL4865775 | 0.89 | GPR119 (0.40) | BACE1GPR119TACR1YAP1JAK2 | |
| SCHEMBL4872229 | 0.88 | REN (0.41) | BACE1BACE2GPR119PRMT5TACR1 | |
| SCHEMBL4871295 | 0.82 | ACHE (0.42) | USP30GPR119TACR1JAK2JAK1 | |
| SCHEMBL4865612 | 0.82 | CTSV (0.41) | KLK7 | |
| SCHEMBL6621977 | 0.80 | GPR119 (0.41) | GPR119PRMT5TACR1JAK2JAK1 | |
| SCHEMBL14265640 | 0.80 | GPR119 (0.45) | USP30GPR119TACR1JAK2JAK1 | |
| SCHEMBL2807737 | 0.79 | BACE1 (0.45) | USP30BACE1BACE2PRMT5TACR1 | |
| SCHEMBL2807739 | 0.79 | BACE1 (0.45) | USP30BACE1BACE2PRMT5TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7338965-B2 | 3,4-disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines | PHARMACIA & UPJOHN COMPANY (US) | 2008-03-04 | — | — | US | disclosed |
| US-20040034031-A1 | 3,4-Disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines | ELAN PHARMACEUTICALS, INC. | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034031-A1 | 3,4-Disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines | BACE1, APP, BACE2 | USP30 1035/4885BACE1 1/4885BACE2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.